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The Siconolfi step test: a valid and reliable
assessment of cardiopulmonary fitness in
older men with prostate cancer
Agnieszka Lemanska1* , Karen Poole1, Jonathan J. Aning2,3, Bruce A. Griffin1, Ralph Manders1, John M. Saxton4,
Joe Wainwright1 and Sara Faithfull1
Abstract
Background: Assessing fitness and promoting regular physical activity can improve health outcomes and early
recovery in prostate cancer. This is however, underutilised in clinical practice. The cardiopulmonary exercise test (CPET)
is increasingly being used pre-treatment to measure aerobic capacity and peak oxygen consumption (VO2peak - a gold
standard in cardiopulmonary fitness assessment). However, CPET requires expensive equipment and may not always be
appropriate. The Siconolfi step test (SST) is simpler and cheaper, and could provide an alternative.
The aim of this study was to evaluate the validity and reliability of SST for predicting cardiopulmonary fitness in men
with prostate cancer. Men were recruited to this two-centre study (Surrey and Newcastle, United Kingdom) after
treatment for locally advanced prostate cancer. They had one or more of three risk factors: elevated blood pressure,
overweight (BMI > 25), or androgen deprivation therapy (ADT). Cardiopulmonary fitness was measured using SST and
cycle ergometry CPET, at two visits three months apart. The validity of SST was assessed by comparing it to CPET. The
VO2peak predicted from SST was compared to the VO2peak directly measured with CPET. The reliability of SST was
assessed by comparing repeated measures. Bland-Altman analysis was used to derive limits of agreement in validity
and reliability analysis.
Results: Sixty-six men provided data for both SST and CPET. These data were used for validity analysis. 56 men
provided SST data on both visits. These data were used for reliability analysis. SST provided valid prediction of the
cardiopulmonary fitness in men > 60 years old. The average difference between CPET and SST was 0.64ml/kg/min
with non-significant positive bias towards CPET (P = 0.217). Bland-Altman 95% limits of agreement of SST with CPET
were ± 7.62ml/kg/min. SST was reliable across the whole age range. Predicted VO2peak was on average 0.53ml/kg/min
higher at Visit 2 than at Visit 1 (P = 0.181). Bland-Altman 95% limits of agreement between repeated SST
measures were ± 5.84 ml/kg/min.
Conclusions: SST provides a valid and reliable alternative to CPET for the assessment of cardiopulmonary
fitness in older men with prostate cancer. Caution is advised when assessing men 60 years old or
younger because the VO2peak predicted with SST was significantly lower than that measured with CPET.
Keywords: Siconolfi step test, Cardiopulmonary fitness, Prostate cancer, Prehabilitation, Clinical assessment
* Correspondence: a.lemanska@surrey.ac.uk
1Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lemanska et al. European Review of Aging and Physical Activity            (2019) 16:1 
https://doi.org/10.1186/s11556-018-0207-9
Introduction
Prostate cancer is the most common cancer in UK men
with almost 47,000 men diagnosed every year [1]. Higher
prevalence is associated with older age and 54% of all new
cases are in men aged 70 and over [1]. Poorer survival is
also associated with older age, in particular for people over
70 [2]. The reasons for this include multi-morbidity, which
can make older men less able to tolerate treatment
and its adverse effects resulting in worse adherence
and non-completion [1, 2]. Furthermore, poor levels
of fitness may impact negatively on clinician and pa-
tient decision-making and consequently reduce access
to curative cancer treatment [3, 4]. With the advent of
early chemotherapy for advanced disease and more
complex adjuvant therapies, assessment of fitness
prior to prostate cancer treatment is needed to opti-
mise clinical outcomes in older men.
Cardiopulmonary fitness has traditionally been assessed
before radical prostatectomy, as part of enhanced recovery
pathways [5] or prior to prehabilitation [6]. It is well recog-
nised that surgery can have a significant impact on catabol-
ism and oxygen demand, and the length and extent of
surgery is directly related to the risk of developing
post-surgery complications [7]. Eligibility for radical prosta-
tectomy is often based on chronological age, but evidence
shows that post-surgery complications are affected more by
comorbidities than age [8]. In clinical trials, even if there is
no age limit, people are required to be “fit for treatment” as
drug tolerance may decrease and toxicity may increase in
those with poor fitness [9]. For example, in the STAMPEDE
prostate cancer trial, only men without a history of signifi-
cant cardiovascular disease were recruited, reducing the
number of older men in the study [10]. Comorbidities can
therefore be a significant barrier to clinical trial entry [3].
Assessing patients in order to decide on the most appro-
priate treatment can be complex. Integrating functional
and specialist assessments has been proposed as part of
the international guidance for managing prostate cancer
[11]. The health status of older people with cancer can be
very diverse. This means that they need a tailored ap-
proach to treatment that considers their cardiopulmonary
fitness as well as their functional performance status [12].
Cardiopulmonary fitness is associated with cardiovascular
risk [13, 14], and like physical strength, can be improved
by physical activity [15, 16].
People with cancer in comparison to age-matched people
without cancer, have lower levels of cardiopulmonary fitness
[17–19]. This can be attributed, in part, to treatment mor-
bidity, but may also be linked to a sedentary lifestyle, which
has been found to increase the risks of some cancers, in-
cluding prostate cancer [20–23]. Exercise has been shown to
alleviate Androgen Deprivation Therapy (ADT) related
symptoms [24] and increase survival in prostate cancer [25,
26]. However, the design and delivery of appropriate lifestyle
interventions requires a safe and simple assessment of fit-
ness, to provide a personalised exercise prescription as a part
of prehabilitation and rehabilitation programmes. Further-
more, it can provide an important pre-treatment benchmark
to motivate patients to improve or sustain their physical
activity levels. The development of a cheap and easy
to implement assessment that provides a valid and re-
liable measure of fitness remains a challenge.
The cardiopulmonary exercise test (CPET) provides a
direct measurement of aerobic capacity and peak oxygen
consumption (VO2peak) and is a gold standard in pre-
operative cardiopulmonary fitness assessment [27, 28].
In prostate cancer, CPET is used for physical assessment
and to evaluate preoperative risks [29], alongside the
American Society of Anesthesiologists Physical Status
Classification System [30, 31]. However, wider imple-
mentation of CPET in routine clinical practice is limited
due to unavailability or high costs. The Siconolfi step
test (SST) is simpler (it can be performed in any clinical
or non-clinical setting) and cheaper than CPET. It has
been validated to predict VO2peak in healthy adults [32,
33]. It has also been evaluated as a cardiopulmonary
fitness assessment in patients with systemic lupus ery-
thematosus [34] and rheumatoid arthritis [35]. To our
knowledge, there is no study to evaluate the validity
and reliability of SST in men with prostate cancer.
SST is performed at a submaximal intensity of exer-
cise, making it safe and suitable for elderly and frail
men or people with disability. In this study, we evalu-
ated SST against CPET and reported on the validity
and reliability of SST in predicting cardiopulmonary
fitness in men with prostate cancer. The reliability re-
fers to the stability of SST in predicting cardiopulmo-
nary fitness across time.
Methods
Study design
Patients were recruited from two centres: the Royal
Surrey County Hospital NHS Foundation Trust, and the
Newcastle upon Tyne Hospitals NHS Foundation Trust.
SST and CPET were first performed at Visit 1 and then
repeated at Visit 2 three months later. Participants were
given their SST and CPET assessment results, but no
lifestyle advice or health intervention was provided.
Study population
Men with localised prostate cancer at 3–36 months’
post-diagnosis and with stable PSA (< 0.4 ng/ml surgery
and radiotherapy patients, and < 10 ng/ml androgen
deprivation therapy (ADT) patients) were invited to
participate. They were recruited only if they had one or
more of the three risk factors: BMI < 18.5 or > 25; elevated
blood pressure; receiving ADT. To enter the study, men
would have completed their prostate cancer treatment a
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minimum of 3months before (6months for brachytherapy).
Men with a history of cardiovascular or pulmonary disease
or receiving active cancer treatment (apart from ADT) were
excluded.
Dataset
A total of 83 men participated in the study at two cen-
tres, and 64 attended both visits (23% attrition). The
study consort diagram is presented in Fig. 1. Data for
66 participants who provided both SST and CPET data
at Visit 1 were available for SST validity analysis. Out
of the 83 study participants, five were excluded from
Visit 1 physical assessments (both SST and CPET)
during the medical check, due to risks identified in
the screening Physical Activity Readiness Questionnaire
[36]. An additional 12 participants were not included in
validity analysis because they had metastatic cancer, miss-
ing SST or CPET data, or were taking beta-adrenergic
blocking medications (inhibition of heart rate elevation
during exercise).
Data for 56 participants who delivered SST data at
both Visits 1 and 2 were available for SST reliability ana-
lysis. Out of the 64 men who attended both visits, eight
were excluded from reliability analysis due to missing
SST data or taking beta-adrenergic blocking medica-
tions. Demographic and treatment characteristics,
Charlson Comorbidity Index (CCI) [37], hand grip
strength [38, 39] and chair sit to stand test [40] results in
the total population, and validity and reliability cohorts
are shown in Table 1.
Fig. 1 Study participants CONSORT diagram
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Fitness assessments
Cardiopulmonary exercise test (CPET)
The participants completed a continuous, incremental
exercise test to volitional exhaustion on an electronically
braked cycle ergometer. The pedalling frequency was
self-selected within a range of 60–90 rpm. After a two
minute warm up against no resistance (0 watt), the inten-
sity of exercise was increased by 20–30 watts/minute.
Participants were encouraged to continue cycling to vol-
itional exhaustion or until a plateau in oxygen consump-
tion was observed. Heart rate (HR) and volume of oxygen
(V02) consumed during exercise (ml/kg/min) were mea-
sured. Peak oxygen consumption (VO2peak) was calcu-
lated as the highest consecutive 20 s period of gas
exchange data in the last minute before volitional ex-
haustion. Participants were not trained athletes and so
Table 1 Demographic and treatment characteristics of the study population & validity and reliability cohorts
Study population
N = 83
Validity cohort
N = 66
Reliability cohort
N = 56
P value
Centre 1.000
Surrey: n (%) 62 (74.7) 52 (78.8) 44 (78.6)
Newcastle: n (%) 21 (25.3) 14 (21.2) 12 (21.4)
Age (years) 0.943
mean (SD) 68.2 (7.4) 68.1 (7.0) 68.2 (7.3)
range 47–83 47–83 47–83
≤ 60 n (%) 14 (16.9) 10 (15.2) 9 (16.1)
> 60 n (%) 69 (83.1) 56 (84.8) 47 (83.9)
Ethnicity 0.199
White: n (%) 80 (96.4) 63 (95.4) 53 (94.6)
Black Caribbean: n (%) 2 (2.4) 2 (3.0) 2 (3.6)
Black African: n (%) 1 (1.2) 1 (1.5) 1 (1.8)
Treatment (men had combined treatments) 0.996
Surgery: n (%) 53 (63.9) 43 (65.1) 36 (64.3)
Radiotherapy: n (%) 26 (31.3) 23 (34.8) 19 (33.9)
Brachytherapy: n (%) 3 (3.6) 3 (4.5) 3 (5.3)
ADT: n (%) 32 (38.6) 26 (39.4) 21 (37.5)
Smoking status 0.926
Non smoker: n (%) 45 (54.2) 36 (54.5) 32 (57.1)
Ex-smoker: n (%) 28 (33.7) 23 (34.8) 19 (33.9)
Smoker: n (%) 3 (3.6) 3 (4.5) 3 (5.4)
Missing: n (%) 7 (8.4) 4 (6.1) 2 (3.6)
Retirement 0.970
Yes: n (%) 19 (22.9) 16 (24.2) 14 (25.0)
No: n (%) 54 (65.1) 42 (63.6) 36 (64.3)
Missing: n (%) 10 (12.0) 8 (12.1) 6 (10.7)
Height (cm): mean (SD) 175.5 (6.5) 175.9 (6.5) 175.5 (6.6) 0.713
Weight (kg): mean (SD) 89.2 (11.8) 88.6 (11.6) 88.7 (11.2) 0.980
Diabetes: n (%) 7 (8.4) 4 (6.1) 3 (5.3) 1.000
Resting blood pressure, systolic (mmHg): mean (SD) 135.7 (15.3) 135.3 (15.1) 136.5 (15.1) 0.651
Resting blood pressure, diastolic (mmHg): mean (SD) 81.4 (10.0) 80.7 (9.1) 81.0 (9.2) 0.853
Waist circumference (cm): mean (SD) 102.2 (9.7) 101.4 (9.4) 101.7 (9.0) 0.886
Hip circumference (cm): mean (SD) 105.5 (7.6) 104.7 (7.3) 104.8 (6.8) 0.921
Grip strength (kg): mean (SD) 38.4 (8.4) 39.3 (7.6) 39.2 (7.8) 0.934
Chair sit to stand (number completed): median (IQR) 13 (5) 13 (5) 13 (5) 0.608
Charlson co-morbidity index (CCI): median (IQR) 6 (3) 5 (2.5) 6 (3) 0.848
Column 1 describes all study participants. Column 2 and 3 describe the cohorts used for Validity (N = 66) and Reliability analysis (N = 56). P value was
calculated to statistically assess the difference between the validity and reliability cohorts
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unaccustomed to maximum physical exertion. There-
fore, a submaximal test was performed, terminated at
volitional exhaustion and VO2peak (not VO2max) was
recorded [41, 42].
Siconolfi step test (SST)
Participants were required to step up and down from a port-
able 10-in. (25.4 cm) step for a maximum of three, three mi-
nute stages. There was one minute rest between stages. The
stepping cadence, timed using a metronome, was increased
at each stage. Stage 1 was at a rate of 17 steps per minute,
stage 2 at 26 steps per minute and stage 3 at 34 steps per
minute [33]. HR was monitored during and after each stage.
Statistical analysis
VO2peak for each patient was directly measured with
CPET and also predicted from SST according to equations
by Siconolfi et al. [33, 43]. The validity of SST was assessed
against CPET from the data collected at Visit 1. The reli-
ability of SST was based on two repeated measures from
Visit 1 and Visit 2. The Pearson correlation coefficient (r)
was used to explore the strength and significance of the
relationship between SST and CPET (validity analysis), and
between repeated SST measures (reliability analysis). The
Intraclass correlation coefficient (ICC) and paired t-test
were used to measure and test the agreement between SST
and CPET, and between repeated SST measures. Finally the
Bland-Altman method [44] was used to calculate the 95%
limits of agreement (LOA) between CPET and STT, and
between repeated SST measures. The smaller the range
between the lower and upper LOA in validity analysis, the
greater the validity of SST is in predicting VO2peak mea-
sured with CPET. Univariate and multivariate linear regres-
sion was used to examine factors that contribute to the
difference between SST and CPET. Factors such as age,
BMI, CCI, grip strength, and chair sit to stand test results
were included in the regression analysis. Statistical signifi-
cance was considered at P < 0.05. The dataset was entered
and managed in SPSS version 22 (SPSS Inc., Chicago,
USA). Statistical analyses were performed in R version
3.0.2 (R Development Core Team, Austria).
Missing data
Data on body weight was missing from one participant at
Visit 2. This was imputed using single regression
imputation [45]. SST or CPET missing data were not im-
puted and only complete cases for Visit 1 and Visit 2 were
included in validity and reliability analysis. This resulted in
a smaller sample available for the reliability analysis than
for the validity analysis. However, to preserve the maximum
available sample number, a different number of samples
was used for each of the analyses.
Results
Sample characteristics
Sample demographic characteristics and treatment data are
presented in Table 1. In total, 66 men (52 from Surrey and
14 from Newcastle) with a mean age 68.1 ± 7.0 years were
included in the validity analysis and 56 men (mean age
68.2 ± 7.3 years) who provided both Visit 1 and Visit 2 SST
data, were included in the reliability analysis. There was no
statistically significant difference in patient characteristics
between the validity and reliability cohorts (Table 1). Most
men recruited to the study (96.4%) were of white ethnicity
and only 3 men (3.6%) were of black ethnicity. Most men
did not smoke (87.9%), with only 3 (3.6%) reporting that
they smoked during the study. 65.1% of men were still
employed. 63.9% were treated with surgery, 31.3% with
radiotherapy and 38.6% of men had ADT.
SST validity analysis
Table 2 shows the results of the Visit 1 SST and CPET
for the validity cohort (N = 66), and for the subsample
Table 2 Validity analysis of Siconolfi step test (SST) against
cardiopulmonary exercise test (CPET)
Validity analysis Validity cohort
(N = 66)
> 60 years olds
(n = 56)
SST
Predicted VO2peak (ml/kg/min):
average (SD) 19.5 (5.1) 19.2 (5.2)
range 10.8–35.5 10.8–35.5
Heart rate (bpm): mean (SD) 141.6 (20.7) 142.2 (21.2)
CPET
Measured VO2peak (ml/kg/min):
average (SD) 21.1 (6.5) 19.8 (5.1)
range 9.9–40.2 9.9–32.5
Heart rate (bpm): mean (SD) 148.7 (15.9) 147.5 (16.2)
Pearson correlation
r 0.69 0.73
P value < 0.001 < 0.001
0.95% CI 0.54–0.80 0.58–0.83
Paired t-test
average difference 1.61 0.64
P value 0.010 0.217
0.95% CI 0.43–3.09 -0.38–1.66
ICC
ICC 0.64 0.73
P value < 0.001 < 0.001
0.95% CI 0.48–0.77 0.58–0.83
Results are presented for all patients that participated in Visit 1 and
provided valid SST and CPET data (validity cohort, N = 66) (column 1),
and the subsample of patients older than 60 years (n = 56) (column 2).
Validity is assessed with Pearson correlation (r), paired t-test and
intraclass correlation coefficient (ICC). Statistical significance was
considered at level of P < 0.05
Lemanska et al. European Review of Aging and Physical Activity            (2019) 16:1 Page 5 of 10
of patients > 60 years old (n = 56). For the whole val-
idity cohort, the average VO2peak predicted from SST
was 19.5 ± 5.1 ml/kg/min and HR at completion was
141.6 ± 20.7 beats per minute (bpm). The VO2peak mea-
sured with CPET was on average 1.61 ± 4.71ml/kg/min
higher than that predicted with SST. This was statistically
significant (P = 0.010). The correlation between predicted
and measured VO2peak was r = 0.69 (p < 0.001, 95%CI 0.54
to 0.80) and ICC was 0.64 (p < 0.001, 95%CI 0.48 to 0.77).
The effect of age on validity of SST: Regression analysis
Age made a significant contribution to the difference
between SST and CPET, being responsible for 16% of
variance. The univariate regression coefficient was − 0.27
(p < 0.001) and the multivariate regression coefficient
was − 0.23 (p = 0.009), which indicates that the differ-
ence was greater for younger men. Other factors included
in the multivariate model (BMI, CCI, grip strength and sit
to stand test) were not statistically significant. When men
60 years old or younger (n = 10) were removed from the
validity analysis the average difference between SST and
CPET decreased to 0.64 ± 3.81ml/kg/min, which was not
statistically significant (p = 0.217). The LOA between SST
and CPET from Bland-Altman validity analysis (Fig. 2a),
were ± 7.62ml/kg/min.
SST reliability analysis
Table 3 shows the results of SST and CPET at Visit 1 and
Visit 2. The average VO2peak values predicted from SST
for the reliability cohort (N = 56) were 19.6 ± 5.2ml/kg/min
at Visit 1 and 20.2 ± 4.5 ml/kg/min at Visit 2. The dif-
ference of 0.53ml/kg/min was not statistically significant
(P = 0.181). Pearson correlation coefficient r between visits
was 0.83 (p < 0.001, 95% CI 0.72 to 0.89) and ICC was 0.81
(p < 0.001, 95% CI 0.70 to 0.89). The 95% Bland-Altman
LOA (Fig. 2b) were from ±5.84ml/kg/min.
The effect of age on validity and reliability of SST –
Comparison of results from visit 1 and visit 2
Figure 3 illustrates the distribution of differences between
SST and CPET for Visit 1 against Visit 2. SST was shown to
be highly reliable across the entire age range, as indicated
Fig. 2 Bland-Altman analysis. a) Validity of Siconolfi step test (SST) against cardiopulmonary exercise test (CPET) using data for n = 56 participants
> 60 years old (≤ 60 years olds were removed according to the results of regression analysis). b) Reliability of Siconolfi step test (SST) using data
for N = 56 participants that provided valid SST data at both visits
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by values falling along and very close to the diagonal (y = x)
line. However, most values for men of 60 years and younger
are outside the upper Bland-Altman LOA on both visits.
This confirms the results of the regression analysis and in-
dicates poor validity of SST for men ≤ 60 years old. CPET
VO2peak values for these men were significantly and con-
sistently higher than those predicted with SST at both visits.
Acceptability of SST and adverse events
SST was found to be simple to perform and was well tol-
erated, with no adverse events. The test was acceptable
to participants with a limited capacity to perform phys-
ical exercise. However, in respect of the latter, caution is
advised when recommending SST to men with comor-
bidities that limit their ability to exercise or compromise
their balance and lower limb function. In addition, men
on beta-blocking medications that inhibit HR elevation
during exercise and render the prediction of VO2peak
invalid, should also be excluded.
Discussion
The purpose of this study was to propose a valid and
reliable methodology for a rapid fitness evaluation that
requires minimal space and was easy to implement. Step
tests have traditionally been used as an alternative to
CPET for assessing cardiopulmonary fitness (e.g. Chester
Step Test) [46–49]. SST was selected because it has
previously been validated to predict VO2peak in healthy
adults [32, 33] and in other clinical populations [34, 35].
The benefits of SST over CPET include simpler and
cheaper implementation as well as equipment that is easily
obtainable and transportable. An important advantage of
SST is also that it fits within limited space e.g. a small clin-
ical room and it can be delivered by non-clinical staff with
minimal training. In this context, SST can also be safer
than CPET because it is performed at a submaximal in-
tensity of exercise.
Notably SST is one of many tests developed for a safe
and pragmatic assessment of cardiopulmonary fitness.
Other submaximal testing procedures that can be used
for indirect estimation of VO2peak include modified
exercise ergometry protocols without spirometry, such
as the Astrand-Ryhming nomogram to predict cardio-
pulmonary fitness [43]. However, the main limitation of
these assessments is that they require an expensive
research-grade cycle ergometer. Treadmill protocols also
exist, as well as walking or running tests [50, 51], but
they are not pragmatic in the context of non-laboratory,
minimal space settings.
This study identifies the important issue of the need
for evaluation of cardiopulmonary fitness of men with
prostate cancer. The assessment is not only important in
risk stratification of men prior to treatment. It also can
be used to guide personalised exercise recommendations
to optimise prehabilitation and rehabilitation interven-
tions. The benefits of exercise on health-related quality
of life are well evidenced in systematic reviews of ran-
domized controlled trials [52, 53]. Improving fitness has
been shown to improve health outcomes and reduce
cancer-related symptoms [54, 55]. Furthermore, in-
creased physical activity is associated with reduced risk
of recurrence and improved survival [26].
The aim of this study was to provide a scalable solu-
tion to these problems by improving men’s engagement
in physical activity and their fitness. A growing body of
evidence in support of the benefits of physical activity
has led to the publication of exercise guidelines for can-
cer survivors [56, 57]. Despite this, it is estimated that
only 10–32% of cancer survivors meet the recommended
physical activity levels [58]. Therefore, an important first
step in promoting physical activity, is to define individ-
ual fitness levels. The results of this study show that SST
can provide a pragmatic and scalable alternative to
CPET for the assessment of cardiopulmonary fitness in
men with prostate cancer. It can be used to help tailor
physical activity interventions to the needs and priorities
of individual patients.
Barriers to the routine implementation of a fitness
assessment in men with prostate cancer include re-
source constraints, time pressures to begin treatment
and limited evidence regarding the benefits of testing
Table 3 Reliability analysis of Siconolfi step test (SST)
Reliability analysis Visit 1
(N = 56)
Visit 2
(N = 56)
SST
Predicted VO2peak (ml/kg/min):
average (SD) 19.6 (5.2) 20.2 (4.5)
range 10.8–35.5 9.6–33.8
Heart rate (bpm): mean (SD) 142.2 (21.3) 142.9 (20.3)
Pearson correlation
r 0.83
P value < 0.001
0.95% CI 0.72–0.89
Paired t-test
average difference 0.53
P value 0.181
0.95% CI -0.25–1.31
ICC
ICC 0.81
P value < 0.001
0.95% CI 0.70–0.89
Repeated measures from Visit 1 (column 1) and Visit 2 (column 2) are presented
for N = 56 participants that provided valid SST data at both visits. Reliability is
assessed with Pearson correlation (r), paired t-test and intraclass correlation
coefficient (ICC). Statistical significance was assessed at level of P < 0.05
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men prior to treatment. CPET is expensive as it re-
quires highly trained staff, specialist facilities and
equipment such as a stationary exercise bike or a
treadmill as well as ECG and oxygen uptake monitor-
ing systems. While the British Thoracic Society 2017/2018
guidance [56] states that CPET in outpatient or day-case
settings in the UK costs £244, this does not cover the
capital expenditure to purchase CPET equipment. In
comparison, SST requires significantly less resources,
no specialist equipment and less space. The equipment
(a 10 in. (25.4 cm) step and a heart rate monitor) is
cheap (total capital expenditure is approximately £162),
small and portable.
CPET is a well validated benchmark measure of car-
diopulmonary fitness, and it was used here to validate
SST. This is an important strength of this study. In
addition, both CPET and SST were performed twice in
the same population, with the repeated measures allow-
ing the reliability of SST to be assessed. Another
strength of this study is the relatively large sample size,
and a wide age range of participants (47–83) that is
representative of the UK prostate cancer population.
The reliability analysis cohort was 15% smaller than
that which was available for the validity analysis. This
was due to study attrition and missing data which are
the main limitations of this study. In addition, VO2peak
(not VO2max) was measured at the point of volitional
termination. This is a more common measure in clin-
ical populations of patients who are not trained athletes
and unaccustomed to maximal intensity exercise. How-
ever, VO2peak is a validated measure of cardiopulmo-
nary fitness and similarly to VO2max it represents
cardiac output, vascularisation and oxygen utilisation
by muscles [41, 42].
Conclusions
This study highlights the importance of conducting valid-
ity and reliability work for SST as a predictor of VO2peak
in men with prostate cancer. Age had a clear effect on the
validity of SST for predicting cardiopulmonary fitness. For
Fig. 3 Scatter plot of differences between cardiopulmonary exercise test (CPET) and Siconolfi step test (SST) at Visit 1 vs Visit 2. The numbers next
to markers show the age of participants. Men ≤ 60 years old are marked in red. The diagonal line is y = x. Vertical and horizontal lines represent
Bland-Altman limits of agreement (LOA) (Fig. 2a)
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men aged 60 years and younger, SST predicted VO2peak
values that were significantly lower than those measured
with CPET. Caution is therefore advised when using
SST to predict VO2peak in patients ≤ 60 years old, and
further work is needed to establish the effect of age
and HR on the validity of SST. Nevertheless, SST was
a stable and reliable measure of fitness over time. In
conclusion, these data present new evidence to sup-
port SST as a valid and reliable method for clinicians
and rehabilitation specialists to assess and monitor
cardiopulmonary fitness in men with prostate cancer.
This assessment could be used to guide personalised
exercise advice in pre- and post-treatment rehabilita-
tion interventions. It could also be used in treatment
decision making as it may help predict short and
long-term outcomes of treatment. SST can be used in
a wide range of clinical and non-clinical settings, and
therefore could provide an alternative to the more ex-
pensive and resource demanding CPET.
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